Celcuity

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Celcuity and other ETFs, options, and stocks.

About CELC

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. 

CEO
Brian F. Sullivan
CEOBrian F. Sullivan
Employees
87
Employees87
Headquarters
Minneapolis, Minnesota
HeadquartersMinneapolis, Minnesota
Founded
2012
Founded2012
Employees
87
Employees87

CELC Key Statistics

Market cap
3.16B
Market cap3.16B
Price-Earnings ratio
-21.62
Price-Earnings ratio-21.62
Dividend yield
Dividend yield
Average volume
823.55K
Average volume823.55K
High today
$74.88
High today$74.88
Low today
$72.05
Low today$72.05
Open price
$74.20
Open price$74.20
Volume
442.54K
Volume442.54K
52 Week high
$83.00
52 Week high$83.00
52 Week low
$7.58
52 Week low$7.58

Stock Snapshot

With a market cap of 3.16B, Celcuity(CELC) trades at $74.52. The stock has a price-to-earnings ratio of -21.62.

During the trading session on 2025-11-08, Celcuity(CELC) shares reached a daily high of $74.88 and a low of $72.05. At a current price of $74.52, the stock is +3.4% higher than the low and still -0.5% under the high.

Trading volume for Celcuity(CELC) stock has reached 442.54K, versus its average volume of 823.55K.

Over the past 52 weeks, Celcuity(CELC) stock has traded between a high of $83.00 and a low of $7.58.

Over the past 52 weeks, Celcuity(CELC) stock has traded between a high of $83.00 and a low of $7.58.

CELC News

Simply Wall St 2d
A Look at Celcuity’s Valuation Following Its Recent 50% Share Price Surge

Celcuity (CELC) shares have climbed over 50% in the past month, sparking fresh questions about what is driving the momentum for this clinical-stage biotech. The...

A Look at Celcuity’s Valuation Following Its Recent 50% Share Price Surge
Investor's Business Daily 2d
Celcuity Eyeing Cancer Treatment Riddle. Stock Flys 534% This Year.

Celcuity (CELC) Chief Executive Brian Sullivan says the biotech company hopes to "solve a 20-year riddle" in cancer treatment. The journey has sent the biotech...

Celcuity Eyeing Cancer Treatment Riddle. Stock Flys 534% This Year.

Analyst ratings

100%

of 9 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own CELC. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.